Sugi Predict

Sugi Predict / Compounds / SCHEMBL2961083

SCHEMBL2961083

SCHEMBL2961083

Cc1cccc(Nc2c(C#N)sc3c2ccc(=O)n3-c2ccccc2Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.39
▸ IDO1 P14902 1/20 0.37
▸ RAB9A P51151 2/20 0.34
▸ CHRNA7 P36544 2/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ PSMD14 O00487 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MMP2 P08253 1/20 0.33
▸ PTPN7 P35236 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ DUSP3 P51452 1/20 0.33
▸ PTPN5 P54829 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PTPN11 Q06124 1/20 0.33
▸ NCOA2 Q15596 1/20 0.33
▸ NCOA1 Q15788 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2952051 0.90 IDO1 (0.38) MAPTIDO1RAB9ACHRNA7NPSR1
SCHEMBL2958665 0.89 WEE1 (0.35) MAPTIDO1KDM4ES1PR4ALDH1A1
SCHEMBL2958784 0.86 IDO1 (0.39) MAPTIDO1RAB9ANPSR1MEN1
SCHEMBL2952952 0.86 CHRNA7 (0.35) IDO1CHRNA7GAA
SCHEMBL2947088 0.84 IDO1 (0.39) MAPTIDO1RAB9ANPSR1MEN1
SCHEMBL2949780 0.82 MAPT (0.47) MAPTRAB9ACHRNA7NPSR1MEN1
SCHEMBL2959756 0.82 IDO1 (0.37) MAPTIDO1RAB9AMEN1POLB
SCHEMBL2954060 0.78 NPC1 (0.37) MAPTIDO1RAB9ANPSR1MEN1
SCHEMBL2949261 0.77 IDO1 (0.39) MAPTIDO1RAB9ANPSR1MEN1
SCHEMBL2950115 0.77 LMNA (0.35) MAPTCHRNA7MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 — — US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 — — US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 — — US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 — — US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 — — US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK MAPT 4305/4885IDO1 100/4885RAB9A 3150/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 MAPT 4495/4885IDO1 215/4885RAB9A 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.